Cambridge Healthtech Institute’s 7th Annual

Advancing Bispecific Antibodies and Combination Therapy to the Clinic

Creating the Killer Combo

April 10-11, 2019

 

One of the leading areas of antibody research is bispecific antibodies. The Seventh Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference will review recent preclinical and clinical results on a variety of bispecific and multi-specific constructs. Thought leaders in the community will review progress and discuss the best strategies for improving targeting, safety and efficacy for applications in immuno-oncology, oncology, CNS and infectious disease.

Preliminary Agenda

WHAT IS WORKING IN THE CLINIC: NEW INNOVATIONS IN BISPECIFIC ANTIBODIES

Bispecific Antibodies for Cancer-Directed Blockade of the PD-1/PD-L1 Immune Checkpoint

Wijnand Helfrich, PhD, Professor of Translational Surgical Oncology, University Medical Center Groningen

Bringing the Tumor-Directed CTLA-4 x OX40 Bispecific Antibody, ATOR-1015, into the Clinic

Charlotte Russell, MD, PhD, CMO, Alligator Bioscience AB

Design Meets Biology – Engineering a PD-1/CTLA-4 Bispecific Antibody to Improve Both Safety and Efficacy

Yariv Mazor, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune

Development of Fully Human Bispecifics for Oncology

Eric Smith, PhD, Director, Bispecifics, Regeneron Pharmaceuticals

Talk Title to be Announced

Eugene Zhukovsky, PhD, CSO, Biomunex Pharmaceuticals

Preclinical and Clinical Development of Best-in-Class Anti-HER2 Bispecifics and Bispecific ADCs

David Poon, PhD, Senior Director, External R&D and Alliances, Zymeworks, Inc.

BISPECIFIC ANTIBODIES OFF THE BEATEN PATH

KEYNOTE PRESENTATION: Overview of Bispecific Antibodies

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

A Highly Efficacious Antibody Mixture against MET-Dependent Tumors

Thomas Tuxen Poulsen, PhD, Principal Scientist, Symphogen A/S

Engineering Bispecific Antibodies for Targeting Tumor Cells with Low Surface Density

Rajkumar Ganesan, PhD, Deptartment of Biologics Research, Janssen Biotherapeutics, Janssen R&D

M7824, a Novel Therapeutic Inhibiting PDL1 and Sequestering TGF-Beta

James L. Gulley, MD, PhD, FACP, Chief, Genitourinary Malignancies Branch, Head, Immunotherapy Group, GMB Director, Medical Oncology Service, Center for Cancer Research, NCI, NIH

Mitra-BiotechLuncheon Presentation to be Announced


* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean




Premier Sponsors


View By: